U.S. Court of Appeals for the Federal Circuit
Coverage of U.S. Court of Appeals for the Federal Circuit in the Nexus archive.
- MIKE DAVIS: Federal court sets dangerous precedent against 99-year-old judge
The U.S. Supreme Court declined to hear U.S. Circuit Judge Pauline Newman's appeal against a suspension imposed by her colleagues on the Federal Circuit, which the author claims is unconstitutional and sets a dangerous precedent. Newman, 99, was suspended over alleged mental competency issues, but independent experts found her fit to serve.
- Supreme Court won't take up 98-year-old judge's bid to hear cases again
The Supreme Court refused to consider a 98-year-old judge's request to resume hearing cases. Judge Pauline Newman, who served on the U.S. Court of Appeals for the Federal Circuit, was suspended due to concerns about her fitness to serve.
- As US Customs refines its tariff refund system, who gets in to apply is under dispute
A federal judge is evaluating whether to order the U.S. government to expedite and expand its tariff refund system after the Supreme Court ruled President Donald Trump's higher duties on global goods were illegal. The Justice Department disputes a court order requiring refunds for all companies, not just those involved in lawsuits, while the Customs and Border Protection agency has launched a phased online system to process claims.
- The $166 billion tariff refund question: Who actually gets paid back?
A U.S. Customs and Border Protection official is set to testify about the government's refund process for $166 billion in tariffs deemed illegal by the Supreme Court. A court judge ordered expanded refunds, but the Justice Department argues only companies involved in lawsuits challenging the tariffs are eligible. The refund process has distributed $20.6 billion so far, with disputes ongoing over eligibility and speed.
- Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products
The Supreme Court unanimously ruled that generic drug manufacturer Hikma Pharmaceuticals cannot be held liable for patent infringements by branded drugmaker Amarin Pharma, rejecting claims that Hikma's labeling, press releases, and website statements actively induced infringement. The case centered on whether Hikma's generic version of Vascepa, used interchangeably with Amarin's patented drug for cardiovascular and hypertriglyceridemia treatments, could be blamed for doctors and pharmacists using the generic for patented purposes.
- Opinions expected
The Supreme Court is expected to release opinions on Thursday, followed by a private conference. House Republicans advanced a constitutional amendment to cap the number of justices at nine. The Trump administration announced new tariffs and challenged a court order requiring refunds for illegal tariffs.